ES2576642T3 - Prevención de infecciones oportunistas en sujetos inmunológicamente comprometidos - Google Patents
Prevención de infecciones oportunistas en sujetos inmunológicamente comprometidos Download PDFInfo
- Publication number
- ES2576642T3 ES2576642T3 ES08862982.9T ES08862982T ES2576642T3 ES 2576642 T3 ES2576642 T3 ES 2576642T3 ES 08862982 T ES08862982 T ES 08862982T ES 2576642 T3 ES2576642 T3 ES 2576642T3
- Authority
- ES
- Spain
- Prior art keywords
- prevention
- lacto
- opportunistic infections
- fucosyl
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Una composición idónea para el uso en la prevención de infecciones oportunistas en individuos inmunológicamente comprometidos que contiene un probiótico del tipo Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve o Bifidobacterium longum y un oligosacárido fucosilado elegido entre el grupo formado por la 2'-fucosil-lactosa, 3'-fucosil-lactosa, difucosil-lactosa, lacto-N-fucopentaosa, lacto-N-fucohexaosa, fucosil-lacto-N-hexaosa y fucosil-lacto-N-neohexaosa.
Description
- nutriente
- por 100 kcal por litro
- Se (µg)
- 2 13
- vitamina A (µg de RE)
- 105 700
- vitamina D (µg)
- 1,5 10
- vitamina E (mg de TE)
- 0,8 5,4
- vitamina K1 (µg)
- 8 54
- vitamina C (mg)
- 10 67
- vitamina B1 (mg)
- 0,07 0,47
- vitamina B2 (mg)
- 0,15 1,0
- niacina (mg)
- 1 6,7
- vitamina B6 (mg)
- 0,075 0,50
- ácido fólico (µg)
- 9 60
- ácido pantoténico (mg)
- 0,45 3
- vitamina B12 (µg)
- 0,3 2
- biotina (µg)
- 2,2 15
- colina (mg)
- 10 67
- Fe (mg)
- 1,2 8
- I (µg)
- 15 100
- Cu (mg)
- 0,06 0,4
- Zn (mg)
- 0,75 5
- 2FL (mg)
- 0,3 2,0
- B. lactis CNCM I-3446
- 2 x107 cfu/g de polvo, bacterias vivas
7
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07123390 | 2007-12-17 | ||
EP07123390A EP2072052A1 (en) | 2007-12-17 | 2007-12-17 | Prevention of opportunistic infections in immune-compromised subjects |
PCT/EP2008/066850 WO2009077352A1 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2576642T3 true ES2576642T3 (es) | 2016-07-08 |
Family
ID=39111664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08862982.9T Active ES2576642T3 (es) | 2007-12-17 | 2008-12-05 | Prevención de infecciones oportunistas en sujetos inmunológicamente comprometidos |
Country Status (18)
Country | Link |
---|---|
US (2) | US9217133B2 (es) |
EP (2) | EP2072052A1 (es) |
CN (1) | CN101909644A (es) |
AU (1) | AU2008337646B2 (es) |
BR (1) | BRPI0820837A2 (es) |
CA (1) | CA2709396A1 (es) |
ES (1) | ES2576642T3 (es) |
IN (1) | IN2010DE04311A (es) |
MX (1) | MX2010006690A (es) |
MY (1) | MY185938A (es) |
PH (1) | PH12010501367B1 (es) |
PL (1) | PL2234627T3 (es) |
PT (1) | PT2234627T (es) |
RU (1) | RU2486910C2 (es) |
SG (1) | SG186657A1 (es) |
UA (1) | UA102830C2 (es) |
WO (1) | WO2009077352A1 (es) |
ZA (1) | ZA201005088B (es) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5766947B2 (ja) | 2007-09-07 | 2015-08-19 | チルドレンズ ホスピタル メディカル センター | 臨床サンプルにおける分泌性のルイス抗原およびシアル化抗原のレベルの疾患リスクの予測指標としての使用 |
EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
DK2451462T3 (en) * | 2009-07-06 | 2017-12-11 | Children's Hospital Medical Center | Inhibition of inflammation with milk oligosaccharides |
RU2530641C2 (ru) | 2009-07-15 | 2014-10-10 | Н.В. Нютрисиа | Фукозиллактоза в качестве неусвояемого олигосахарида, идентичного грудному молоку, с новой функциональной пользой |
WO2011008086A1 (en) | 2009-07-15 | 2011-01-20 | N.V. Nutricia | Mixture of non-digestible oligosaccharides for stimulating the immune system |
US9408880B2 (en) | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
CN102946742A (zh) * | 2010-04-27 | 2013-02-27 | N·V·努特里奇亚 | 人乳寡糖在婴儿营养物中的用途 |
WO2011136637A1 (en) * | 2010-04-27 | 2011-11-03 | N.V. Nutricia | Use of human milk oligosaccharides in infant nutrition |
WO2011150939A1 (en) | 2010-06-01 | 2011-12-08 | Glycom A/S | Polymorphs of 2'-o-fucosyllactose and producing thereof |
EP2465509A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
EP2455387A1 (en) * | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
NZ612455A (en) * | 2010-12-31 | 2015-02-27 | Abbott Lab | Human milk oligosaccharides to promote growth of beneficial bacteria |
NZ612386A (en) * | 2010-12-31 | 2015-02-27 | Abbott Lab | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
EP3338784B1 (en) | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
US9539269B2 (en) | 2010-12-31 | 2017-01-10 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
MY166945A (en) | 2010-12-31 | 2018-07-25 | Abbott Lab | Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof |
CN103391783A (zh) | 2010-12-31 | 2013-11-13 | 雅培制药有限公司 | 使用人乳寡糖改善呼吸道健康的方法 |
MX338174B (es) * | 2010-12-31 | 2016-04-06 | Abbott Lab | Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios. |
NZ612472A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
WO2012107865A2 (en) † | 2011-02-10 | 2012-08-16 | Wyeth Llc | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
US9567361B2 (en) * | 2011-05-13 | 2017-02-14 | Glycosyn LLC | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
JP2014516589A (ja) | 2011-06-20 | 2014-07-17 | エイチ.ジェイ.ハインツ カンパニー | プロバイオティック組成物及び方法(probioticcompositionandmethods) |
CA2842672A1 (en) | 2011-07-22 | 2013-01-31 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
SG2014013478A (en) | 2011-08-29 | 2014-05-29 | Abbott Lab | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
CN103889240B (zh) * | 2011-10-18 | 2016-09-14 | 雀巢产品技术援助有限公司 | 用于增加胰岛素敏感性和/或降低胰岛素抵抗性的组合物 |
BR112014008425A2 (pt) * | 2011-10-18 | 2017-04-11 | Nestec Sa | composição para o uso na promoção de angiogênese intestinal e de absorção de nutriente e de tolerância a alimentação enteral e/ou na prevenção e/ou no tratamento de inflamação intestinal e/ou na recuperação após a lesão e a cirurgia intestinal |
US9173910B2 (en) | 2012-02-29 | 2015-11-03 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
CN104363962A (zh) * | 2012-03-27 | 2015-02-18 | 雅培制药有限公司 | 用于使用人乳寡糖调节细胞介导的免疫的方法 |
DK2708145T3 (en) * | 2012-09-14 | 2016-07-18 | Abbott Lab | Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals |
WO2014130789A1 (en) | 2013-02-21 | 2014-08-28 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
US10165788B2 (en) * | 2013-06-17 | 2019-01-01 | The Regents Of The University Of California | Methods and compositions for improved digestion of milk oligosaccharides |
EP2815757A1 (en) * | 2013-06-17 | 2014-12-24 | Hestia Investments | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa |
US11135232B2 (en) | 2013-11-15 | 2021-10-05 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
CN114468302A (zh) | 2013-11-15 | 2022-05-13 | 雀巢产品有限公司 | 用于预防或治疗有风险婴儿或幼儿的urt感染的组合物 |
MX2016006220A (es) | 2013-11-15 | 2016-08-08 | Nestec Sa | Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños nacidos por cesarea. |
US10568896B2 (en) | 2013-11-19 | 2020-02-25 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
CA2942732C (en) | 2014-04-08 | 2023-01-03 | Abbott Laboratories | Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides |
DK3209308T3 (da) * | 2014-10-24 | 2022-10-03 | Evolve Biosystems Inc | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf |
CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US20170354696A1 (en) * | 2014-11-26 | 2017-12-14 | Abbott Laboratories | Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic |
US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US10835544B2 (en) | 2014-12-08 | 2020-11-17 | Glycom A/S | Synthetic composition for regulating satiety |
US10987368B2 (en) | 2014-12-08 | 2021-04-27 | Glycom A/S | Synthetic composition for preventing or treating CVD |
WO2016139328A1 (en) | 2015-03-05 | 2016-09-09 | Nestec S.A. | Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children |
EP3265099B1 (en) * | 2015-03-05 | 2023-08-09 | Glycom A/S | Human milk oligosaccharides for treating acute respiratory tract infections |
AU2016227600B2 (en) | 2015-03-05 | 2020-05-21 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children |
US10821124B2 (en) * | 2015-03-05 | 2020-11-03 | Societe Des Produits Nestle S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
US10857167B2 (en) | 2015-04-28 | 2020-12-08 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
CA3017357A1 (en) * | 2016-03-11 | 2017-09-14 | Evolve Biosystems, Inc. | A transient commensal microorganism for improving gut health |
EP3471562A4 (en) * | 2016-06-15 | 2020-07-29 | Glycom A/S | SYNTHETIC COMPOSITIONS WITH MOTHER MILK OLIGOSACCHARIDES FOR THE PREVENTION AND TREATMENT OF DISEASES |
WO2019031961A1 (en) | 2017-08-11 | 2019-02-14 | N.V. Nutricia | OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION |
EP3675882A4 (en) | 2017-08-30 | 2021-07-28 | Pendulum Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
EP3583858A1 (en) * | 2018-06-20 | 2019-12-25 | DuPont Nutrition Biosciences ApS | Compositions for treating or preventing gut barrier dysfunction |
US11554131B2 (en) * | 2018-05-31 | 2023-01-17 | Glycom A/S | Mixture of HMOs for treating autoimmune diseases |
US20220241354A1 (en) * | 2019-06-05 | 2022-08-04 | Morinaga Milk Industry Co., Ltd. | Composition |
JP2023502260A (ja) * | 2019-11-20 | 2023-01-23 | アボット・ラボラトリーズ | クロストリジウム・ディフィシル感染症を治療する栄養組成物 |
CN112870232A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99提升肠道细菌感染抗性和肠道免疫力的应用 |
CN113491289A (zh) * | 2020-04-03 | 2021-10-12 | 内蒙古伊利实业集团股份有限公司 | 可提升生物体对金黄色葡萄球菌感染的抵御能力的母乳低聚糖 |
CN114504109B (zh) * | 2020-11-16 | 2024-02-09 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
CN116195740A (zh) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | 可提升生物体对金黄色葡萄球菌感染抵御能力的益生元与益生菌组合物 |
CN116195629A (zh) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | 婴儿双歧杆菌ylgb-1496在抗衰老、提高先天免疫方面的新应用 |
WO2024013393A1 (en) * | 2022-07-15 | 2024-01-18 | Dsm Ip Assets B.V. | Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+ |
WO2024068747A1 (en) * | 2022-09-27 | 2024-04-04 | Société des Produits Nestlé S.A. | Uses of bifidobacterium longum transitional microorganism |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
DK0768375T4 (da) * | 1992-07-06 | 2002-09-16 | Nestle Sa | Mælkesyrebakterier |
EP0577903B1 (fr) | 1992-07-06 | 1997-12-17 | Societe Des Produits Nestle S.A. | Agent antigastrite |
FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
US6045854A (en) | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
US5902743A (en) * | 1998-03-20 | 1999-05-11 | Wisconsin Alumni Research Foundation | Probiotic bifidobacterium strain |
US20020019991A1 (en) * | 1998-04-30 | 2002-02-14 | Abbott Laboratories | Compositions containing an alpha 1,2-fucose linkage and uses thereof |
US6841149B1 (en) * | 1998-05-29 | 2005-01-11 | Agri-King, Inc. | Probiotic mixture intended for monogastric animals to control intestinal flora populations |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
ES2416287T3 (es) * | 2003-06-23 | 2013-07-31 | Nestec S.A. | Empleo de una fórmula nutritiva para la función óptima de la barrera intestinal |
PT1675481E (pt) | 2003-10-24 | 2009-01-02 | Nutricia Nv | Composição sinbiótica para bebés |
JP5236189B2 (ja) | 2003-12-05 | 2013-07-17 | チルドレンズ ホスピタル メディカル センター | オリゴ糖組成物および感染症の治療における該組成物の使用 |
US7137361B2 (en) | 2004-06-22 | 2006-11-21 | Federal-Mogul World Wide, Inc. | Cylinder head gasket with one-way coolant flow valve |
EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
PT1993577E (pt) | 2006-03-10 | 2014-05-27 | Nutricia Nv | Uso de sacarídeos não digestivos para proporcionar a uma criança o melhor começo após o nascimento |
BRPI0721442A2 (pt) | 2007-03-13 | 2013-01-15 | Nutricia Nv | uso de uma composiÇço |
US8197872B2 (en) * | 2007-05-17 | 2012-06-12 | The Regents Of The University Of California | Human milk oligosaccharides to promote growth of beneficial gut bacteria |
EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
ES2395838T3 (es) * | 2007-12-21 | 2013-02-15 | Compagnie Gervais Danone | Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium |
-
2007
- 2007-12-17 EP EP07123390A patent/EP2072052A1/en not_active Withdrawn
-
2008
- 2008-06-16 PH PH12010501367A patent/PH12010501367B1/en unknown
- 2008-12-05 RU RU2010129685/15A patent/RU2486910C2/ru active
- 2008-12-05 PT PT88629829T patent/PT2234627T/pt unknown
- 2008-12-05 SG SG2012092268A patent/SG186657A1/en unknown
- 2008-12-05 CN CN2008801249067A patent/CN101909644A/zh active Pending
- 2008-12-05 BR BRPI0820837-9A patent/BRPI0820837A2/pt not_active Application Discontinuation
- 2008-12-05 EP EP08862982.9A patent/EP2234627B1/en not_active Revoked
- 2008-12-05 US US12/808,053 patent/US9217133B2/en active Active
- 2008-12-05 WO PCT/EP2008/066850 patent/WO2009077352A1/en active Application Filing
- 2008-12-05 AU AU2008337646A patent/AU2008337646B2/en active Active
- 2008-12-05 MX MX2010006690A patent/MX2010006690A/es active IP Right Grant
- 2008-12-05 PL PL08862982.9T patent/PL2234627T3/pl unknown
- 2008-12-05 CA CA2709396A patent/CA2709396A1/en not_active Abandoned
- 2008-12-05 MY MYPI2010002780A patent/MY185938A/en unknown
- 2008-12-05 ES ES08862982.9T patent/ES2576642T3/es active Active
- 2008-12-08 UA UAA201008634A patent/UA102830C2/ru unknown
-
2010
- 2010-06-16 IN IN4311DEN2010 patent/IN2010DE04311A/en unknown
- 2010-07-16 ZA ZA2010/05088A patent/ZA201005088B/en unknown
-
2012
- 2012-08-17 US US13/588,745 patent/US20120308527A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IN2010DE04311A (es) | 2010-11-12 |
PL2234627T3 (pl) | 2016-12-30 |
RU2486910C2 (ru) | 2013-07-10 |
WO2009077352A1 (en) | 2009-06-25 |
PT2234627T (pt) | 2016-07-26 |
US9217133B2 (en) | 2015-12-22 |
ZA201005088B (en) | 2017-03-27 |
MX315565B (es) | 2010-09-10 |
EP2234627B1 (en) | 2016-05-25 |
RU2010129685A (ru) | 2012-01-27 |
SG186657A1 (en) | 2013-01-30 |
US20100260720A1 (en) | 2010-10-14 |
EP2234627A1 (en) | 2010-10-06 |
UA102830C2 (ru) | 2013-08-27 |
PH12010501367B1 (en) | 2009-06-25 |
CA2709396A1 (en) | 2009-06-25 |
CN101909644A (zh) | 2010-12-08 |
US20120308527A1 (en) | 2012-12-06 |
MY185938A (en) | 2021-06-14 |
AU2008337646A1 (en) | 2009-06-25 |
BRPI0820837A2 (pt) | 2015-06-16 |
AU2008337646B2 (en) | 2014-07-17 |
MX2010006690A (es) | 2010-09-10 |
EP2072052A1 (en) | 2009-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2576642T3 (es) | Prevención de infecciones oportunistas en sujetos inmunológicamente comprometidos | |
ES2477882T3 (es) | Probióticos, IgA secretora e infección | |
Alexander et al. | Gut microbiota modulation of chemotherapy efficacy and toxicity | |
JP7387587B2 (ja) | クロストリジウム・ディフィシル感染症の治療における新たな使用 | |
CN105979952B (zh) | 协同细菌组合物以及其制造方法和用途 | |
JP6130379B2 (ja) | 胃酸過多の薬物処置中に失われる胃自体の障壁効果を修復することができるプロバイオティック細菌と組み合わされたn−アセチルシステインおよび/またはマイクロカプセル化胃保護型リゾチームを含む組成物 | |
ES2561253T3 (es) | Bacterias probióticas que tienen actividad antioxidante y uso de las mismas | |
JP2022028787A (ja) | 相乗的細菌組成物並びにその生成及び使用の方法 | |
Rajkowska et al. | Probiotic activity of Saccharomyces cerevisiae var. boulardii against human pathogens | |
NZ593708A (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
JP2016529309A5 (es) | ||
AR076862A1 (es) | Microorganismos no replicantes y su efecto de refuerzo inmunologico. composicion. metodo para aumentar efectividad de probioticos | |
DK1855550T3 (da) | Næringspræparat med probiotika | |
JP2014512376A (ja) | 胃酸過多症の薬理学的処置中に失われる胃のバリア効果を回復させることができるプロバイオティック細菌を含む組成物 | |
Reid | Probiotic and prebiotic applications for vaginal health | |
CN110917220A (zh) | 治疗组合物及其使用方法 | |
BR112013020312A2 (pt) | composições simbióticas para restauração e reconstituição da microbiota intestinal | |
AR109085A1 (es) | Uso de probióticos en el tratamiento y/o la prevención de la dermatitis atópica | |
PL406050A1 (pl) | Nowy szczep Bifidobacterium breve | |
AR076677A1 (es) | Bifidobacterium longum ncc2705 (cncm i-2618) y trastornos inmunes. | |
MX2008006546A (es) | Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria. | |
FI3789501T3 (fi) | Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen | |
AR107921A1 (es) | Uso de probióticos en el tratamiento y/o la prevención de la enfermedad de la psoriasis | |
RU2013148473A (ru) | Бактериальные штаммы, способные метаболизировать оксалаты | |
RU2010147885A (ru) | Применение пробиотических бактерий для лечения гипергомоцистеинемии |